Clinical implications of 10-formyltetrahydrofolate dehydrogenase expression in hormone receptor-positive breast cancer

1

ALDH1L1 expression is higher in non-tumor tissues compared to cancer tissues, indicating its potential role as a tumor suppressor.
2

Higher ALDH1L1 expression correlates with smaller tumor size and lower tumor aggressiveness in hormone receptor-positive breast cancer.
3

ALDH1L1 expression is associated with improved overall and disease-free survival, particularly in luminal A and HER2+ subtypes.
4

The study confirms that reduced ALDH1L1 expression is linked to aggressive clinicopathologic features in breast cancer.
5

ALDH1L1 may serve as a favorable biomarker and therapeutic target in hormone receptor-positive breast cancer.

1